Figure 9. Resveratrol enhances the expression of FoxO1 and the cytolytic susceptibility of melanoma.

Panel A and B: C57BL/6 mice were implanted s.c. with B16F10 melanoma cells (2×10⁵ cells/mouse) and orally administered with resveratrol. On day 9, mice were treated with IL-2 as described in Fig. 1. The mice were sacrificed for evaluation of VLS on day 12. The primary tumors in the skin were resected and weighed. Total RNA was extracted. Expression of FoxO1 was detected by QPCR (A). The relative expression was normalized to the endogenous 18S. The mean ±SEM of weight is shown (B). Panel C: B16F10 cells were cultured with vehicle (Veh), IL-2 (IL) (1000 units/ml), or resveratrol at the indicated dose for 24 h. Total RNA was extracted. Expression of FoxO1 was detected by QPCR. Panel D: LAK cells were generated by culturing splenocytes from naïve mice with IL-2 (1000 units/ml) for 48 h. B16F10 cells were incubated with resveratrol (25 µM) for 2 h and labeled with ⁵¹Cr. The labeled B16F10 cells were then added to the LAK cells. After 4 h, the release of ⁵¹Cr was measured and percent cytotoxicity was calculated. Statistical analysis was performed at each effector to target ratio and showed p<0.001.